Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vanutide cridificar

Drug Profile

Vanutide cridificar

Alternative Names: AAC 001; ACC-001; Active beta-amyloid immunotherapeutic conjugate; Aβ immunotherapeutic conjugate; CRM 197; Peptide-CRM Conjugate; PF-05236806; PF-5236806

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Corporation; Wyeth
  • Developer JANSSEN Alzheimer Immunotherapy; Pfizer
  • Class Alzheimer vaccines; Antidementias; Carrier proteins; Drug conjugates; Immunoconjugates; Peptide fragments
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2016 Pfizer terminates a phase II long-term extension trial in Alzheimer's disease in USA (NCT00960531)
  • 01 Feb 2014 Pfizer and JANSSEN Alzheimer Immunotherapy complete a phase II trial in Alzheimer's disease in USA (NCT01227564)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top